Understanding immunotherapy outcomes in lung cancer after treatment stops
Immunotherapy in Lung Cancer: Which Treatment After Immunotherapy Cessation: A Prospective Registry From the European Lung Cancer Working Party
European Lung Cancer Working Party · NCT04465942
This study looks at patients with advanced lung cancer who have stopped immunotherapy to see how it affects their survival and what treatment options they choose next.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Lung Cancer Working Party (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 5 sites (Brussels and 4 other locations) |
| Trial ID | NCT04465942 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with stage IV non-small cell lung cancer (NSCLC) or unresectable stage III NSCLC who are receiving immunotherapy. It aims to document the reasons for stopping immunotherapy and the subsequent treatment approaches taken. Patients will be registered at the time of immunotherapy initiation, and data will be collected on survival rates and disease-free survival after treatment cessation. The study will provide insights into the therapeutic landscape following immunotherapy.
Who should consider this trial
Good fit: Ideal candidates include patients with stage IV or unresectable stage III NSCLC who are receiving immunotherapy for the first time.
Not a fit: Patients who have previously received adjuvant immunotherapy for earlier stages of NSCLC may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of treatment pathways and outcomes for lung cancer patients after immunotherapy.
How similar studies have performed: While the approach of assessing outcomes after immunotherapy cessation is not widely tested, similar studies have shown promise in understanding treatment dynamics in lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of non-small cell lung cancer (NSCLC) * Stage IVA/IVB and unresectable and non irradiable stage III NSCLC naïve of immunotherapy. * Patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment. * Availability for participating in the detailed follow-up of the protocol. * Signed informed consent. Exclusion Criteria: * Patients receiving adjuvant immunotherapy for stage I-III NSCLC are not eligible * Tumours for which TNM stage at time of study inclusion cannot be assessed. * History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval). * Any type of immunotherapy for previous cancer
Where this trial is running
Brussels and 4 other locations
- Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet — Brussels, Belgium (RECRUITING)
- Department of Pneumology CHU Charleroi — Charleroi, Belgium (NOT_YET_RECRUITING)
- Department of Pneumology Hôpital Saint-Joseph — Gilly, Belgium (NOT_YET_RECRUITING)
- Hôpital Ambroise Paré — Mons, Belgium (NOT_YET_RECRUITING)
- Hôpital Mont-Godinne — Yvoir, Belgium (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Thierry Berghmans, MD, PhD
- Email: thierry.berghmans@bordet.be
- Phone: 003225413191
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Carcinoma, Non-Small-Cell Lung, Immunotherapy